PMID- 32260359
OWN - NLM
STAT- MEDLINE
DCOM- 20210120
LR  - 20210120
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 25
IP  - 7
DP  - 2020 Apr 4
TI  - A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in 
      Patients with Type 2 Diabetes.
LID - 10.3390/molecules25071667 [doi]
LID - 1667
AB  - Thrombopoietin (THPO) is a circulatory cytokine that plays an important role in 
      platelet production. The presence of anti-THPO antibody relates to 
      thrombocytopenia and is rarely seen in hematopoietic and autoimmune diseases. To 
      date, there had been no reports that focused on the anti-THPO antibody in 
      patients with type 2 diabetes mellitus (T2DM). To evaluate prevalence of the 
      anti-THPO antibody in patients with T2DM and the relationship between anti-THPO 
      antibody and platelet count, a cross-sectional study was performed on 82 patients 
      with T2DM. The anti-THPO antibody was measured by ELISA using preserved sera and 
      detected in 13 patients. The average platelet count was significantly lower in 
      patients with the anti-THPO antibody than in those without the anti-THPO 
      antibody. Multivariate linear regression analyses showed a significant 
      relationship between the anti-THPO antibody and platelet count, after adjusting 
      for other variables. To our best knowledge, this was the first report on the 
      effect of the anti-THPO antibody on platelet count in patients with T2DM. Further 
      investigation is needed to validate the prevalence and pathological significance 
      of the anti-THPO antibody in patients with T2DM.
FAU - Fukuda, Takuya
AU  - Fukuda T
AUID- ORCID: 0000-0001-6939-8465
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
FAU - Hamaguchi, Masahide
AU  - Hamaguchi M
AUID- ORCID: 0000-0002-8651-4445
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
FAU - Osaka, Takafumi
AU  - Osaka T
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
AD  - Department of Endocrinology and Diabetology, Ayabe City Hospital, Ayabe 623-0011, 
      Japan.
FAU - Hashimoto, Yoshitaka
AU  - Hashimoto Y
AUID- ORCID: 0000-0002-8794-0550
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
FAU - Ushigome, Emi
AU  - Ushigome E
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
FAU - Asano, Mai
AU  - Asano M
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
FAU - Yamazaki, Masahiro
AU  - Yamazaki M
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
FAU - Fukuda, Eriko
AU  - Fukuda E
AUID- ORCID: 0000-0003-3086-3707
AD  - Molecular Profiling Research Center for Drug Discovery, National Institute of 
      Advanced Industrial Science and Technology, Tokyo 135-0064, Japan.
AD  - ProteoBridge Corporation, Tokyo 135-0064, Japan.
FAU - Yamaguchi, Kei
AU  - Yamaguchi K
AD  - Molecular Profiling Research Center for Drug Discovery, National Institute of 
      Advanced Industrial Science and Technology, Tokyo 135-0064, Japan.
AD  - ProteoBridge Corporation, Tokyo 135-0064, Japan.
FAU - Ogawa, Koji
AU  - Ogawa K
AD  - ProteoBridge Corporation, Tokyo 135-0064, Japan.
FAU - Goshima, Naoki
AU  - Goshima N
AD  - Molecular Profiling Research Center for Drug Discovery, National Institute of 
      Advanced Industrial Science and Technology, Tokyo 135-0064, Japan.
AD  - ProteoBridge Corporation, Tokyo 135-0064, Japan.
FAU - Fukui, Michiaki
AU  - Fukui M
AD  - Department of Endocrinology and Metabolism, Kyoto Prefectural University of 
      Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan.
LA  - eng
GR  - JP 17K15780/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20200404
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Antibodies)
RN  - 9014-42-0 (Thrombopoietin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies/*blood
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*blood/immunology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Platelet Count
MH  - Regression Analysis
MH  - Thrombopoietin/*immunology
PMC - PMC7181124
OTO - NOTNLM
OT  - autoantibody
OT  - cross-sectional study
OT  - diabetes
OT  - platelet
COIS- Michiaki Fukui have received grants, honoraria, and research supports from 
      AstraZeneca plc.; Astellas Pharma Inc.; Nippon Boehringer Ingelheim Co., Ltd.; 
      Daiichi Sankyo Co., Ltd.; Eli Lilly Japan K.K.; Kyowa Hakko Kirin Company Ltd.; 
      Kissei Pharmaceutical Co., Ltd.; MSD K.K.; Mitsubishi Tanabe Pharma Corporation; 
      Novo Nordisk Pharma Ltd.; Sanwa Kagaku Kenkyusho Co., Ltd.; Sanofi K.K.; Ono 
      Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Co., Ltd. The sponsors were 
      not involved in the study design; in the collection, analysis, interpretation of 
      data; in the writing of this manuscript; or in the decision to submit the article 
      for publication. The authors, their immediate families, and any research 
      foundations with which they are affiliated have not received any financial 
      payments or other benefits from any commercial entity related to the subject of 
      this article. The authors declare that although they are affiliated with a 
      department that is supported financially by the pharmaceutical company, the 
      authors received no current funding for this study and this does not alter their 
      adherence to all the journal policies on sharing data and materials. The other 
      authors have nothing to disclose.
EDAT- 2020/04/09 06:00
MHDA- 2021/01/21 06:00
PMCR- 2020/04/04
CRDT- 2020/04/09 06:00
PHST- 2020/03/01 00:00 [received]
PHST- 2020/03/28 00:00 [revised]
PHST- 2020/04/03 00:00 [accepted]
PHST- 2020/04/09 06:00 [entrez]
PHST- 2020/04/09 06:00 [pubmed]
PHST- 2021/01/21 06:00 [medline]
PHST- 2020/04/04 00:00 [pmc-release]
AID - molecules25071667 [pii]
AID - molecules-25-01667 [pii]
AID - 10.3390/molecules25071667 [doi]
PST - epublish
SO  - Molecules. 2020 Apr 4;25(7):1667. doi: 10.3390/molecules25071667.